TCGA-34-5239-01A-21R-1820-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- G2M_CHECKPOINT+0.440
- ANGIOGENESIS+0.430
- MITOTIC_SPINDLE+0.400
- ALLOGRAFT_REJECTION+0.390
- UV_RESPONSE_DN+0.380
- E2F_TARGETS+0.370
- APICAL_JUNCTION+0.330
- MYC_TARGETS_V2+0.330
- TGF_BETA_SIGNALING+0.320
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.360
- SPERMATOGENESIS-0.290
- GLYCOLYSIS-0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
- XENOBIOTIC_METABOLISM-0.260
- FATTY_ACID_METABOLISM-0.230
- PEROXISOME-0.230
- MTORC1_SIGNALING-0.200
- CHOLESTEROL_HOMEOSTASIS-0.190
- UV_RESPONSE_UP-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10899983 | — | — | 0.827 |
| 2 | TCGA-85-8287-01A-11R-2296-07 | — | cohortSQ1 | 0.825 |
| 3 | TCGA-98-8023-01A-11R-2247-07 | — | cohortSQ1 | 0.816 |
| 4 | SRR8518214 | — | D | 0.795 |
| 5 | TCGA-FD-A62S-01A-11R-A30C-07 | — | — | 0.786 |
| 6 | SRR4296078 | — | cohortSQ1 | 0.779 |
| 7 | SRR8613802 | — | D | 0.775 |
| 8 | SRR934821 | — | — | 0.765 |
| 9 | MDT-AP-1349 | Med | Medulloblastoma | 0.764 |
| 10 | TCGA-68-8251-01A-11R-2296-07 | — | cohortSQ1 | 0.762 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |